Syndax
CompanyUnited States
Syndax develops one asset. Mostly antibody acting on inflammation and CSF1R; based in the United States.
- 1
- Asset
- Furthest stage
- Not known
- 0
- Trials
- 1
- Signal
Pipeline
1Blocks CSF1R signaling to reduce macrophage-mediated inflammation and fibrosis.
Discontinued, Antibody, Inflammation, CSF1R
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Signals1
- Similar companies6